Company Overview
Marksans Pharma Limited is a pharmaceutical company specializing in generic formulations and OTC products for regulated markets including the UK, USA, Australia, and Europe. The company has built a strong export-focused business with consistent growth and improving profitability.
Share Screener Snapshot
| Parameter | Value |
|---|---|
| NSE Symbol | MARKSANS |
| Sector | Pharmaceuticals |
| Industry | Generic Formulations |
| Market Cap | Mid Cap |
| Business Model | Export-Oriented Pharma |
| Promoter Holding | ~44% |
| Debt Level | Low |
| Dividend | Yes |
| Export Revenue | Major Contributor |
Consolidated Balance Sheet (₹ Crore)
| Particulars | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity Capital | 45 | 45 | 45 |
| Reserves | 2,020 | 2,422 | 2,978 |
| Borrowings | 244 | 322 | 343 |
| Other Liabilities | 372 | 451 | 494 |
| Total Liabilities | 2,681 | 3,240 | 3,861 |
| Fixed Assets | 776 | 982 | 1,088 |
| Investments | 27 | 1 | 0 |
| Other Assets | 1,869 | 2,230 | 2,758 |
| Total Assets | 2,681 | 3,240 | 3,861 |
Source: Consolidated financial statements.
Financial Growth
| Metric | FY24 | FY25 |
|---|---|---|
| Revenue (₹ Crore) | 2,177 | 2,623 |
| Revenue Growth | 17.6% | 20.5% |
| Cash & Short-Term Investments (₹ Crore) | 701 | 706 |
| Receivables (₹ Crore) | 464 | 554 |
| Inventory (₹ Crore) | 618 | 846 |
The company has delivered steady revenue growth while maintaining a strong cash position and expanding its manufacturing capabilities.
Fundamental Strengths
✅ Strong Export Business
A significant share of revenue comes from regulated markets such as the UK and USA, which generally offer better margins.
✅ Healthy Balance Sheet
Net worth has increased substantially over the last three years, with reserves growing from ₹1,700 crore in FY23 to nearly ₹3,000 crore in FY26.
✅ Growing Cash Reserves
Cash and short-term investments exceed ₹700 crore, providing financial flexibility for expansion and acquisitions.
✅ Regulatory Approvals
The company continues receiving approvals in key export markets, supporting future product launches.
✅ Consistent Profitability
Marksans Pharma has maintained healthy margins and return ratios, making it a popular long-term pharma stock among investors.
Risk Factors
- Dependence on export markets.
- Currency fluctuation risks.
- Regulatory compliance requirements.
- Generic drug pricing pressure.
- Raw material cost volatility.
Technical Screener Checklist
| Indicator | Status |
|---|---|
| Revenue Growth | Strong |
| Profit Growth | Positive |
| Debt-to-Equity | Low |
| Cash Position | Strong |
| Export Exposure | High |
| Institutional Interest | Positive |
| Long-Term Trend | Positive |
Long-Term Investment View
Marksans Pharma has evolved into a strong export-oriented pharmaceutical company with growing revenues, expanding reserves, healthy cash balances, and a relatively conservative balance sheet. Investors looking for a mid-cap pharma stock with international exposure often track Marksans Pharma for long-term wealth creation potential. However, valuation, regulatory approvals, and export-market performance should be monitored regularly.
0 Comments